Bernard Klein
Overview
Explore the profile of Bernard Klein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
4542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rossi J, Chiang H, Lu Z, Levon K, van Rhee F, Kanhai K, et al.
Front Immunol
. 2022 Aug;
13:919489.
PMID: 35928820
Background: Dysregulated interleukin (IL)-6 production can be characterised by the levels present, the kinetics of its rise and its inappropriate location. Rapid, excessive IL-6 production can exacerbate tissue damage in...
2.
Rossi J, Chiang H, Klein B
JAMA Intern Med
. 2021 Apr;
181(7):1018-1019.
PMID: 33818612
No abstract available.
3.
Villard O, Armanet M, Couderc G, Bony C, Moreaux J, Noel D, et al.
Stem Cell Res Ther
. 2020 May;
11(1):190.
PMID: 32438928
An amendment to this paper has been published and can be accessed via the original article.
4.
Villard O, Armanet M, Couderc G, Bony C, Moreaux J, Noel D, et al.
Stem Cell Res Ther
. 2020 Apr;
11(1):158.
PMID: 32303252
Background: Mesenchymal stromal cells (MSCs) represent an interesting tool to improve pancreatic islet transplantation. They have immunomodulatory properties and secrete supportive proteins. However, the functional properties of MSCs vary according...
5.
Gourzones C, Bellanger C, Lamure S, Gadacha O, de Paco E, Vincent L, et al.
Cancers (Basel)
. 2019 Mar;
11(4).
PMID: 30925767
Background: Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development...
6.
Vikova V, Jourdan M, Robert N, Requirand G, Boireau S, Bruyer A, et al.
Theranostics
. 2019 Feb;
9(2):540-553.
PMID: 30809292
Human multiple myeloma tumor cell lines (HMCLs) have been a cornerstone of research in multiple myeloma (MM) and have helped to shape our understanding of molecular processes that drive tumor...
7.
Requirand G, Robert N, Boireau S, Vincent L, Seckinger A, Bouhya S, et al.
Cytometry B Clin Cytom
. 2018 Nov;
96(3):209-214.
PMID: 30417559
Background: Mutiple myeloma (MM) is a neoplasia characterized by the accumulation of malignant plasma cells (PC) in the bone marrow. Although proliferation markers have been studied in MM, none of...
8.
Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, et al.
Br J Cancer
. 2018 Mar;
118(8):1062-1073.
PMID: 29500406
Background: Multiple myeloma (MM) is the second most common hematologic malignancy. Aberrant epigenetic modifications have been reported in MM and could be promising therapeutic targets. As response rates are overall...
9.
Alaterre E, Raimbault S, Goldschmidt H, Bouhya S, Requirand G, Robert N, et al.
Oncotarget
. 2017 Dec;
8(58):98931-98944.
PMID: 29228738
Multiple myeloma (MM) is a B cell neoplasia characterized by clonal plasma cell (PC) proliferation. Minimal residual disease monitoring by multi-parameter flow cytometry is a powerful tool for predicting treatment...
10.
Alaterre E, Raimbault S, Garcia J, Reme T, Requirand G, Klein B, et al.
Cytometry B Clin Cytom
. 2017 Sep;
94(3):484-492.
PMID: 28865180
Background: Multiple myeloma (MM) is an incurable disease characterized by clonal plasma cell (PC) proliferation within the bone marrow (BM). Next-generation flow cytometry has become the reference tool to follow...